anti mc 1  (Alomone Labs)

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: Male WT and MC1R-null (null) mice were treated with vehicle or Adriamycin (ADR) in the presence or absence of NDP-MSH co-treatment. Spot urine was collected on indicated time points after ADR or vehicle treatment. All animals were killed on Day 7, and kidneys and serum harvested and examined. (A) Urine samples (1.5 μl) were subjected to SDS-PAGE and staining with Coomassie Brilliant Blue. Bovine serum albumin (BSA, 20, 40, μg) served as standard controls; (B) Quantification of urine albumin levels adjusted with urine creatinine concentrations. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status at each time point; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status at each time point (n=6); (C) Representative micrographs demonstrate periodic acid–Schiff (PAS) staining (scale bar=50μm) of mouse kidneys. ADR-induced injury is featured by podocytic swelling and vacuolization, glomerular synechiae, glomerular capillary congestion, collapse and/or obliteration accompanied by hyaline material and/or mesangial matrix expansion as well as protein casts in tubulointerstitium; (D) Semi-quantitative morphometric analysis of PAS-stained kidney sections for glomerular damage scores. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status (n=6); (E) Semi-quantitative morphometric analysis of PAS-stained kidney sections for protein cast scores. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status (n=6); (F) Serum samples were processed for creatinine assay. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status (n=6).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: SDS Page, Staining, Mutagenesis

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: Male WT and ADR mice were treated as elaborated in Figure 1. (A) Kidney specimens were procured from mice on day 7 after ADR or saline treatment and processed for electron microscopy (scale bar=1μm) and fluorescent immunohistochemistry staining (scale bar=20μm) for indicated molecules, including synaptopodin (SYNPO), desmin and WT-1, or in combination with TUNEL staining for apoptotic cells. Black arrowheads highlight injured podocytes with evident foot process effacement. White arrowheads indicate WT-1+ podocytes with positive staining for desmin or TUNEL; (B) Absolute counting of the number of apoptotic podocytes in glomeruli, expressed as the number of cells positive for both TUNEL and WT-1 in each glomerulus. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status(n=6); (C) Absolute counting of the number of foot processes per unit length of glomerular basement membrane (GBM) on electron micrographs#P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status(n=6); (D) Glomeruli were isolated from kidneys by the magnetic beads-based approach and processed for immunoblot analysis for indicated molecules. (E-G) Immunoblots were subjected to densitometric analysis. Data were presented as arbitrary units of densitometric ratios of indicated proteins to GAPDH as folds of the non-ADR-injured WT mice. #P<0.05 versus non-ADR-injured animals with the same MC1R mutation status; *P<0.05 versus ADR alone-treated animals with the same MC1R mutation status (n=6).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: Saline, Electron Microscopy, Immunohistochemistry, Staining, TUNEL Assay, Mutagenesis, Membrane, Isolation, Magnetic Beads, Western Blot

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: Primary podocytes derived from WT and MC1R-null mice were grown to confluence and treated with ADR or vehicle in the presence or absence of NDP-MSH (10−7M). (A) Cells were grown on the collagen coated transwell filters and after indicated treatments for 24h paracellular permeability assay was carried out to determine the filtration barrier function of podocytes monolayers. Culture media in the top chamber were collected at 1 or 3h during the paracellular permeability assay and subjected to quantification of the albumin influx across podocyte monolayers. Duration of albumin incubation is shown next to the x-axis. #P < 0.05 vs non-ADR-injured podocytes with the same MC1R mutation status (n = 6); *P < 0.05 vs ADR alone-treated podocytes with the same MC1R mutation status. (n = 6). (B) Primary podocytes were treated and subsequently scratch was processed using a 10μL pipette. Phase-contrast micrographs were taken immediately after wounding (0 h) and after migration for 24 h. Scale bar = 100 μm. (C) Quantification by computerized morphometric analysis of the cell migration area following the indicated treatments. #P < 0.05 vs non-ADR-injured podocytes with the same MC1R mutation status (n = 6); *P < 0.05 vs ADR alone-treated podocytes with the same MC1R mutation status. (n = 6).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: Derivative Assay, Permeability, Filtration, Incubation, Mutagenesis, Transferring, Migration

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: Primary podocytes derived from WT and MC1R-null mice were treated with ADR or vehicle in the presence or absence of NDP-MSH (10−7M) for 24h. (A) Cells were fixed and subjected to staining for cytoskeletal F-actin with rhodamine phalloidin and to fluorescent immunocytochemistry staining for synaptopodin (SYNPO) and desmin. Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Representative micrographs of phase contrast microscopy and florescent microscopy are shown (Scale bar=20μm). (B) Cell lysates were subjected to immunoblot analysis for indicated molecules. (C and D) Immunoblots were subjected to densitometric analysis. Data were presented as arbitrary units of densitometric ratios of indicated proteins to GAPDH as folds of the non-ADR-injured WT cells. #P<0.05 versus non-ADR-injured cells with the same MC1R mutation status; *P<0.05 versus ADR alone treated cells with the same MC1R mutation status (n=4).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: Derivative Assay, Staining, Immunocytochemistry, Microscopy, Western Blot, Mutagenesis

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: Primary podocytes derived from WT and MC1R-null mice were treated with ADR or vehicle in the presence or absence of NDP-MSH (10−7M) for 24 h. (A) Cells were fixed and subjected to TUNEL staining for apoptotic cells. Cells were counterstained with propidium iodide (PI) (Scale bar=20μm). (B) Absolute counting of the numbers of TUNEL positive apoptotic podocytes expressed as percentage of the total number of podocyte nuclei per high-power field. #P < 0.05 vs non-ADR-injured podocytes with the same MC1R mutation status (n = 6); *P < 0.05 vs ADR alone-treated podocytes with the same MC1R mutation status. (n = 6). (C) Cellular viability was assessed by the MTT assay. #P < 0.05 vs non-ADR-injured podocytes with the same MC1R mutation status (n = 6); *P < 0.05 vs ADR alone-treated podocytes with the same MC1R mutation status. (n = 6). (D) Cell lysates were subjected to immunoblot analysis for indicated molecules. (E) Immunoblots were subjected to densitometric analysis. Data were presented as arbitrary units of densitometric ratios of cleaved caspase-3 to GAPDH as folds of the non-ADR-injured WT cells. #P<0.05 versus non-ADR-injured cells with the same MC1R mutation status; *P<0.05 versus ADR alone treated cells with the same MC1R mutation status (n=4).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: Derivative Assay, TUNEL Assay, Staining, Mutagenesis, MTT Assay, Western Blot

Journal: Clinical science (London, England : 1979)

Article Title: Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling

doi: 10.1042/CS20200016

Figure Lengend Snippet: (A) Primary podocytes derived from WT and MC1R-null mice were cultured under physiologic conditions and processed for fluorescent immunocytochemistry staining for MC1R with 4′,6-diamidino-2-phenylindole (DAPI) counterstaining. B16F10 cells served as a positive control and preimmune IgG control for MC1R staining. B16F10 cells with MC1R silencing (siMC1R) served as a negative control. (Scale bar=30μm). (B) Cells lysate were subjected to immunoblot analysis for MC1R. The MC1R specific band is indicated. The asterisk indicates nonspecific bands probed by the antibody. (C) Immunoblots were subjected to densitometric analysis. Data were presented as arbitrary units of densitometric ratios of MC1R to GAPDH as folds of the control group. #P<0.05 versus control group (n=4). (D) Cryosections of WT kidneys were processed for fluorescent immunohistochemistry staining for MC1R (green). Representative micrographs are shown. Enlarged views show colocalization of MC1R staining (green) with CD31 staining (red) in glomeruli (Scale bars=10μm).

Article Snippet: Samples were stained with primary antibodies against synaptopodin (1:100, PROGEN Biotechnik GmbH, Heidelberg, Germany), desmin (1:100, Santa Cruz Biotechnology, CA), Wilms’ tumor 1 (WT-1; 1:100, Santa Cruz Biotechnology, CA), MC1R (Alomone Labs, Jerusalem, Israel) , or CD31 (Cell Signaling Technology) overnight at 4°C, followed by Alexa Fluor-conjugated secondary antibodies (Invitrogen).

Techniques: Derivative Assay, Cell Culture, Immunocytochemistry, Staining, Positive Control, Control, Negative Control, Western Blot, Immunohistochemistry